XML 28 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Statement of Cash Flows [Abstract]    
Net income (loss) $ 34,356 $ (94,061)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 563 456
Stock-based compensation expense 9,740 14,743
Loss on extinguishment of debt 6,239 0
Amortization of debt discounts and debt issuance costs 182 6,411
Accrual of interest paid in kind (11,825) 3,908
Gain on sale of other equity investments (639) 0
Other 1,146 921
Changes in assets and liabilities:    
Trade and other receivables (2,581) (11,550)
Inventory (2,087) (192)
Prepaid expenses and other current assets 1,049 (851)
Other long-term assets 519 99
Accounts payable 472 (966)
Accrued compensation and benefits (4,779) 6,678
Accrued clinical trial liabilities 549 (2,390)
Accrued collaboration liabilities 5,873 6,055
Deferred revenue 28,159 195,469
Other current and long-term liabilities 7,457 6,346
Net cash provided by (used in) operating activities 74,393 131,076
Cash flows from investing activities:    
Purchases of property and equipment (2,312) (1,083)
Proceeds from sale of property and equipment 14 112
Proceeds from sale of other equity investments 639 0
Proceeds from maturities of restricted cash and investments 5,650 2,650
Purchase of restricted cash and investments (6,150) (4,150)
Proceeds from sale of investments 37,294 17
Proceeds from maturities of investments 200,893 58,340
Purchases of investments (154,809) (199,396)
Net cash provided by (used in) investing activities 81,219 (143,510)
Cash flows from financing activities:    
Proceeds from exercise of stock options 12,980 2,207
Proceeds from employee stock purchase plan 3,053 479
Taxes paid related to net share settlement of equity awards (2,331) (2,059)
Repayment of convertible notes and term loan payable (185,788) 0
Net cash (used in) provided by financing activities (172,086) 627
Net decrease in cash and cash equivalents (16,474) (11,807)
Cash and cash equivalents at beginning of year 151,686 [1] 141,634
Cash and cash equivalents at end of year 135,212 129,827
Supplemental cash flow disclosure - non-cash investing and financing activity:    
Construction-in-progress deemed to have been acquired under build-to-suit lease $ 14,530 $ 0
[1] The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.